Immunotherapy combo tested for rare kidney cancer, but trial stopped early
NCT ID NCT03274258
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 people with a rare and aggressive kidney cancer called renal medullary carcinoma. The goal was to see if the drugs could shrink tumors or slow cancer growth. However, the study was terminated early, so the results are limited and it is unclear how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and ipilimumab (immunotherapy drugs)
- What this could lead to
- If it works, this could point toward a treatment option for a rare and aggressive kidney cancer.
- What could go wrong
- The trial was terminated early with only 10 participants, so results are very limited. Immunotherapy can cause serious side effects like organ inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY MEDULLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Wheat germ supplement studied for immune boost in advanced cancer
- Gene test may guide kidney cancer therapy choice